Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy of a 14-day venetoclax regimen in combination with a hypomethylating agent for Acute Myeloid Leukemia: A single-center retrospective analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ECEiline CaiHTH E TurnerIMIbrahim N. Muhsen

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows 14-day venetoclax with azacitidine improves response in elderly AML, suggesting a safer regimen.

Key Points

  • This study examines the efficacy and safety of a 14-day venetoclax regimen with a hypomethylating agent in treating acute myeloid leukemia (AML).
  • Retrospective analysis at a single center
  • Included adults with newly diagnosed or relapsed/refractory AML
  • Patients received a 14-day course of venetoclax with azacitidine or decitabine
  • Primary outcome was 4-week all-cause mortality
  • Overall survival and neutropenic fever rates were secondary endpoints.
  • Completed remission (CR) or CR with incomplete count recovery in 52% of patients
  • Overall response rate was 70%
  • Median overall survival was 9.2 months
  • 14% four-week mortality rate
  • Neutropenic fever occurred in 56% of patients, with pneumonia being most common.

Cite This Study

Cai et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d378https://doi.org/10.1182/blood-2025-6994
View Full Paper
Ask AI
Bookmark
Share